person reading

About Macrogenics Inc - Company Information, Overview, History and Profile

What does Macrogenics Inc do?

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).

Macrogenics Inc Management structure

All Gross Remunerations are in USD
Dr. Scott Koenig, M.D.,PhD
Director, President and Chief Executive Officer
-
2024
Gross Remuneration
Year
Ms. Lynn Cilinski
Vice President, Controller and Treasurer
-
2024
Gross Remuneration
Year
Ms. Beth Smith
Vice President, Controller, Treasurer and Principal Accounting Officer
-
2024
Gross Remuneration
Year

Macrogenics Inc Board of directors

All Gross Remunerations are in USD
Dr. Scott Koenig, M.D.,PhD
Director, President and Chief Executive Officer
-
2024
Gross Remuneration
Year
Mr. William K. Heiden
Chairman of the Board
-
2024
Gross Remuneration
Year